Diabetic kidney disease (DKD) is a common complication of diabetes, affecting 30-50% of people living with diabetes. DKD leads to adverse clinical outcomes, including end-stage renal failure requiring dialysis or transplantation, and cardiovascular disease.
Anaxis Pharma is developing a novel therapy targeting necroptosis, a regulated form of inflammatory cell death implicated in DKD progression. By interrupting this pathway, our treatment aims to mitigate inflammation, preserve kidney function, and delay or prevent kidney failure.
This TTRA-funded project will support key preclinical and translational activities to advance our drug candidate toward clinical readiness. The research will focus on demonstrating efficacy in disease models, refining pharmacology, and establishing a development strategy in alignment with regulatory expectations.
If successful, this first-in-class approach could represent a significant therapeutic breakthrough in the management of diabetic kidney disease, improving health outcomes and reducing the long-term burden on patients and the healthcare system.
